Achaogen Announces New Employment Inducement Grants
January 25, 2018 08:00 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen to Present at J.P. Morgan Healthcare Conference
January 03, 2018 16:01 ET
|
Achaogen, Inc.
– Company presentation scheduled for January 11, 2018 – SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company...
Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape
January 02, 2018 08:01 ET
|
Achaogen, Inc.
-- C-Scape was well tolerated across all doses studied in Phase 1 trial, with no drug-drug interaction between the previously approved compounds when dosed in combination -- -- C-Scape is a...
Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
January 02, 2018 08:01 ET
|
Achaogen, Inc.
-- Investigational drug has potential to treat certain MDR gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) -- -- FDA sets action date of June 25, 2018 -- SOUTH SAN...
Achaogen Announces New Employment Inducement Grants
December 22, 2017 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Appoints Blake Wise Chief Executive Officer
December 11, 2017 16:01 ET
|
Achaogen, Inc.
- Dr. Kenneth Hillan to become President, R&D - - Succession designed to lead Achaogen through next phase of growth as a commercial-stage company - - Transition effective January 1, 2018 - ...
Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
November 30, 2017 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Announces New Employment Inducement Grants
November 24, 2017 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 08, 2017 16:01 ET
|
Achaogen, Inc.
-- Plazomicin New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTI) and bloodstream infections (BSI) -- ...
Achaogen to Present at the Stifel 2017 Healthcare Conference
November 06, 2017 08:01 ET
|
Achaogen, Inc.
-- Company presentation scheduled for November 14, 2017 at 8:45 a.m. EST -- SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage...